Kestine Lyo is a medicinal product containing the active substance ebastine, which is an antihistamine that supports the management of allergic symptoms. The primary use is applied across domains where additional symptomatic support is needed.

It is commonly used across conditions presenting with acute episodes. The medication is considered relevant for easing the overall symptom burden in conditions presenting with systemic or localized discomfort, specifically seasonal and perennial allergic rhinitis (hay fever), and idiopathic chronic urticaria (hives).

This therapeutic approach may assist with maintaining functional stability and provides supportive relief when symptoms related to physical discomfort interfere with routine activities. The medication is often used when symptoms intensify and supportive relief is needed during difficult episodes of heightened discomfort.

Quick Fact: Supports patients during episodes of heightened discomfort

The use of this medication contributes to improved comfort during periods of heightened symptoms. It is considered relevant for easing the symptoms that create noticeable physiological strain. The medication may assist with addressing symptom clusters that may become intense or disruptive.

“The medication assists with maintaining functional stability and supports general well-being during symptomatic phases.”

Regulatory References

1. HPRA Summary of Product Characteristics for Kestine

The eligibility for using Kestine Lyo is defined by patient age, pre-existing conditions, and physiological status, based strictly on official regulatory labeling.

Contraindicated Populations

Category	Status	Constraint
Hypersensitivity	Prohibited	Patients with a known allergy to ebastine or any of the lyophilisate excipients.
Liver Function	Prohibited	Patients with Severe Hepatic Insufficiency must not use the medicine.
Excipient-related	Prohibited	Individuals with Phenylketonuria (PKU) (due to Aspartame) or certain rare hereditary sugar intolerances.

Age and Condition Eligibility

Population	Status	Official Regulatory Note
Adults and Adolescents	Approved	Approved for patients aged 12 years and older.
Children under 12	Not Recommended	Safety and efficacy have not been established in this age group.
Renal Impairment	Permitted	Use is acceptable; no dose adjustment is necessary for renal impairment.
Mild to Moderate Liver Impairment	Permitted	Use is acceptable; no dose adjustment is necessary in these cases.

Conditional Use and Reproductive Status

Use of Kestine Lyo requires caution in patients with pre-existing cardiac risks, such as known QTc interval prolongation or Hypokalaemia (low potassium levels). Use is not recommended during pregnancy and lactation, primarily due to insufficient data to establish safety in these periods.

Interactions with other medicines and products

Kestine Lyo contains ebastine. Its interaction profile primarily involves medicines that affect the body's metabolic processes, specifically those that inhibit the cytochrome P450 3A4 (CYP3A4) enzyme system, which is responsible for converting ebastine into its active metabolite, carebastine.

Interacting Medicine Categories	Specific Examples (Officially Listed)	Interaction Mechanism
Imidazole-type Antifungals	Ketoconazole, Itraconazole	CYP3A4 inhibition, leading to increased plasma concentrations of ebastine and carebastine.
Macrolide Antibiotics	Erythromycin	CYP3A4 inhibition, leading to increased plasma concentrations of ebastine and carebastine.
Anti-tuberculosis Drugs	Rifampicin	CYP3A4 induction, leading to lower plasma levels of ebastine and carebastine, potentially reducing the antihistaminic effect.

Interaction Guidance:

• Caution is advised when prescribing ebastine alongside medicines containing imidazole-type antifungals, macrolide antibiotics, or rifampicin.
• Although concomitant use of Ketoconazole or Erythromycin significantly increases systemic exposure to ebastine and carebastine, clinical studies suggest this increase is not associated with clinically significant pharmacodynamic consequences at therapeutic doses.

Other Noted Interactions:

• Ebastine has been studied and found to have no interaction with Theophylline, Warfarin, Cimetidine, Diazepam, or Alcohol.
• Food interaction: Administration with food can increase the blood plasma levels of the active metabolite by 1.5- to 2.0-fold, but this is reported to cause no modification in the clinical effect of the product.

Kestine Lyo (ebastine) functions primarily as a highly selective histamine H1-receptor antagonist. Following oral administration, the parent compound, ebastine, undergoes hepatic metabolism via the cytochrome P450 enzyme system (specifically CYP3A4) to its main active metabolite, carebastine. Carebastine exhibits negligible central nervous system penetration, localizing its primary effect to peripheral tissues, particularly those in the respiratory tract and skin vasculature.

Carebastine acts as an inverse agonist or competitive antagonist at the H1 receptor, a Gq protein-coupled receptor. By stabilizing the receptor in its inactive conformation, it prevents the binding and subsequent activation of endogenous histamine. This blockade inhibits the histamine-mediated downstream signaling cascade, which involves the activation of phospholipase C and the subsequent increase in intracellular inositol trisphosphate (IP3) and calcium ion (Ca^2+) concentration.

System-level physiological modulation involves the counteraction of histamine-induced effects, including the reduction of increased capillary permeability, localized vasodilation, and non-vascular smooth muscle contraction. These actions collectively limit the overall systemic propagation of histamine-driven cellular responses.

Administration Principles and Dosing

Kestine Lyo is an oral lyophilisate approved for use in adults and adolescents 12 years of age and above. The medication follows a once-daily (OD) administration schedule, establishing a consistent temporal pattern for use. The standard regimen is 10 mg of ebastine taken once a day. For more severe symptoms, the dose may be increased to a maximum of 20 mg once daily, an adjustment permitted within the official dosing range.

The administration of the oral lyophilisate is independent of mealtimes and can be taken with or without food. The unique dosage form dictates a specific procedural structure: the lyophilisate must be placed directly onto the tongue where it disperses almost instantly, meaning no water or other liquid is required for swallowing the dose. Due to its sensitive nature, the dose must be handled with dry hands and administered immediately after the blister pack is opened.

Population-Specific Use

Official labeling addresses administration in specific patient populations. The daily dose should not exceed 10 mg for individuals diagnosed with severe hepatic insufficiency. However, no specific dose adjustment is considered necessary for patients with mild to moderate hepatic impairment or for those with any degree of renal impairment. Treatment is generally continued for an extended duration until the corresponding symptoms resolve.

Research Evidence / Overview of Studies for Kestine Lyo (Ebastine)

---

Evidence for Use in Allergic Rhinitis (Hay Fever)

Research exploring Kestine Lyo's active ingredient, Ebastine, was studied for allergic rhinitis, a condition characterized by fluctuating or episodic manifestations such as sneezing, runny nose, and itchy eyes. Studies primarily consist of Randomized Controlled Trials (RCTs) and large meta-analyses that consolidate trial data. These studies was evaluated in adults and adolescents using study designs that included comparisons against a placebo and other active medications.

The primary outcomes studied monitored and recorded outcomes related to physical discomfort, often measured using a Total Symptom Score (TSS), which is a composite score of multiple nasal and ocular allergy symptoms. Research describes changes measured during the study period, with data show patterns related to symptom measurements observed in the studied populations. Research exploring short-term symptom changes typically featured short-term follow-up durations, with many trials observing responses over defined time intervals of just a few weeks.

---

Evidence for Use in Chronic Urticaria (Hives)

The use of this medication in chronic urticaria—a condition involving periods of heightened symptoms characterized by hives and severe itching—has also was evaluated in controlled research settings. These studies focused on adults who experienced these disruptive episodes, often with symptoms that varied in intensity. The research examined outcomes such as the severity of itching (pruritus) and the number of wheals present on the skin, which are outcomes capturing phases of heightened symptom activity.

Studies included controlled trials where the active ingredient was observed in populations compared to placebo, and also in comparative research scenarios that evaluated different treatment options. The findings describe patterns observed in the studies related to the changes in these specific patient-reported outcomes describing perceived discomfort. Longer-term studies monitored patient responses over defined time intervals extending up to three months, with some research exploring maintenance of low symptom activity for up to a year.

---

What is Still Uncertain About the Research

Research for Kestine Lyo is ongoing, and the evidence highlights what is known and what is still uncertain across the full scope of its use. Evidence quality varies across studies, and some areas still require further clinical exploration.

Key research limitation frames identified in the body of research include that comparative evidence is lacking for some of the higher-dose regimens studied for chronic urticaria. Findings concerning the drug's effect on nasal congestion are not as consistent as those for other rhinitis symptoms. The existing studies provide context regarding short-term changes, but research exploring long-term outcomes and the durability of effects over extended periods is limited.

Key Studies & References

1. Ebastine Teva 10 mg Orodispersible Tablets - Summary of Product Characteristics (SPC)
2. Kestine 10 mg Tablets - Summary of Product Characteristics (HPRA)

Common questions about Kestine Lyo (FAQ)

---

Q: Is it normal to feel dizzy after taking Kestine Lyo?

A: Official product information describes dizziness as an uncommon or rare side effect, meaning it may affect only a small percentage of people who use the medicine. Its occurrence is infrequent based on regulatory data, but is part of the established safety profile.

---

Q: Why might a doctor prescribe Kestine Lyo over another antihistamine?

A: Kestine Lyo's active substance, ebastine, is categorized as a highly selective H1 receptor antagonist with prolonged action, meaning it is designed for sustained relief. Official descriptions also highlight that the 'Lyo' form is an orodispersible tablet, which is a convenient, waterless administration method.

---

Q: What if a user experiences a rare or severe side effect from Kestine Lyo?

A: Regulatory documents list rare but serious adverse reactions, such as symptoms of shock or anaphylaxis (a severe allergic reaction) and signs of liver dysfunction (like yellowing of the skin). These severe reactions are noted as requiring cessation of the medicine, and official documentation indicates that immediate medical attention is necessary.

---

Q: Does taking Kestine Lyo at a specific time of day matter?

A: Kestine Lyo is intended for once-daily administration and can be taken with or without food. While regulatory information does not mandate a specific time of day, it is noted that taking the dose at the same time every day helps maintain consistent concentrations of the medicine in the body.

---

Q: Does Kestine Lyo work better for certain types of allergies?

A: The active ingredient, ebastine, has been evaluated through clinical trials for both allergic rhinitis (hay fever) and chronic urticaria (hives). Clinical trials describing the use of ebastine have been conducted for both conditions, though research summaries suggest that findings related to nasal congestion may be less consistent than for other rhinitis symptoms.

---

Q: Are there different strengths of Kestine Lyo available?

A: Official product information confirms that Kestine Lyo is available in different dosage strengths as orodispersible tablets. The availability of multiple strengths allows for flexible treatment adjustments based on the severity of symptoms.

---

Q: What should I do if I forget to take a dose of Kestine Lyo?

A: Official information regarding a missed dose describes two common scenarios: taking the dose if remembered soon, or skipping it if the next dose is due shortly. In the latter scenario, the missed dose is skipped entirely. Regulatory documents specify that taking two doses to compensate for a missed dose is not advised.

---

Q: Is Kestine Lyo suitable for people who are elderly?

A: According to the official posology (dosing rules), no specific dose adjustment is typically required for elderly patients based on the results of clinical studies.

---

Q: Can I take Kestine Lyo if I am also taking another allergy medicine?

A: Regulatory product leaflets note that ebastine may potentially enhance the effects of other antihistaminic medicines. Official safety guidelines indicate that disclosure of all concomitant allergy medications to a healthcare provider is necessary.

---

Q: Can Kestine Lyo cause weight gain?

A: Official lists of side effects include increased appetite as an uncommon adverse reaction, affecting between 1 in 100 and 1 in 1,000 people. Direct weight gain is not explicitly listed as a common or uncommon side effect; only increased appetite is noted in some regulatory documents.

---

Q: Is Kestine Lyo gluten-free?

A: Regulatory documents contain a full list of inactive ingredients, or excipients, including lactose and aspartame. However, these documents do not explicitly confirm or certify the medication as being gluten-free.

---

Q: Can Kestine Lyo be used for mosquito bites?

A: The approved uses listed in official regulatory indications are limited to the treatment of symptoms associated with allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). The labeling does not include localized insect bite reactions.

---

Q: Does Kestine Lyo have any known interactions with herbal supplements?

A: Official drug information requires disclosure of all medicines and dietary supplements being taken, which includes herbal products, for evaluation of potential interactions. This is due to the potential for unforeseen interactions that could affect how Kestine Lyo works.

---

Q: What is the maximum duration of treatment mentioned in official documents?

A: Official prescribing information states that the duration of use is determined by the treating physician and generally continues until the relevant symptoms resolve. A specific maximum time period for continuous use is not explicitly specified in the regulatory posology.

How to Store and Dispose of Kestine Lyo

The storage and disposal of Kestine Lyo (ebastine oral lyophilisate) must adhere strictly to the conditions specified in official regulatory labeling to maintain product stability.

Official Storage Requirements

The medicine must be stored below 30°C and must be protected from light and moisture. It is required to keep the lyophilisate in the original blister package and it must not be refrigerated or frozen. The orodispersible tablet should only be removed from the blister immediately prior to administration due to its moisture sensitivity. All medication must be kept out of the sight and reach of children.

Official Disposal Rules

Unused or expired Kestine Lyo must not be disposed of via household waste or wastewater. Patients are instructed to ask their pharmacist how to correctly discard the medicine, ensuring compliance with local requirements for pharmaceutical waste.